These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 9544217)

  • 1. (3R,4S)-3-[4-(4-fluorophenyl)-4-hydroxypiperidin-1-yl]chroman-4,7-diol: a conformationally restricted analogue of the NR2B subtype-selective NMDA antagonist (1S,2S)-1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidino)- 1-propanol.
    Butler TW; Blake JF; Bordner J; Butler P; Chenard BL; Collins MA; DeCosta D; Ducat MJ; Eisenhard ME; Menniti FS; Pagnozzi MJ; Sands SB; Segelstein BE; Volberg W; White WF; Zhao D
    J Med Chem; 1998 Mar; 41(7):1172-84. PubMed ID: 9544217
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modulation of [3H]MK-801 binding to NMDA receptors in vivo and in vitro.
    Murray F; Kennedy J; Hutson PH; Elliot J; Huscroft I; Mohnen K; Russell MG; Grimwood S
    Eur J Pharmacol; 2000 Jun; 397(2-3):263-70. PubMed ID: 10844123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. (1S,2S)-1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidino)-1-propanol: a potent new neuroprotectant which blocks N-methyl-D-aspartate responses.
    Chenard BL; Bordner J; Butler TW; Chambers LK; Collins MA; De Costa DL; Ducat MF; Dumont ML; Fox CB; Mena EE
    J Med Chem; 1995 Aug; 38(16):3138-45. PubMed ID: 7636876
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of pan- and subtype-selective N-methyl-D-aspartate receptor antagonists on cortical spreading depression in the rat: therapeutic potential for migraine.
    Peeters M; Gunthorpe MJ; Strijbos PJ; Goldsmith P; Upton N; James MF
    J Pharmacol Exp Ther; 2007 May; 321(2):564-72. PubMed ID: 17267580
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CP-101,606, a potent neuroprotectant selective for forebrain neurons.
    Menniti F; Chenard B; Collins M; Ducat M; Shalaby I; White F
    Eur J Pharmacol; 1997 Jul; 331(2-3):117-26. PubMed ID: 9274969
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CP-101,606, an NR2B subunit selective NMDA receptor antagonist, inhibits NMDA and injury induced c-fos expression and cortical spreading depression in rodents.
    Menniti FS; Pagnozzi MJ; Butler P; Chenard BL; Jaw-Tsai SS; Frost White W
    Neuropharmacology; 2000 Apr; 39(7):1147-55. PubMed ID: 10760358
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-activity analysis of a novel NR2C/NR2D-preferring NMDA receptor antagonist: 1-(phenanthrene-2-carbonyl) piperazine-2,3-dicarboxylic acid.
    Feng B; Tse HW; Skifter DA; Morley R; Jane DE; Monaghan DT
    Br J Pharmacol; 2004 Feb; 141(3):508-16. PubMed ID: 14718249
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The NR2B-selective N-methyl-D-aspartate receptor antagonist Ro 25-6981 [(+/-)-(R*,S*)-alpha-(4-hydroxyphenyl)-beta-methyl-4-(phenylmethyl)-1-piperidine propanol] potentiates the effect of nicotine on locomotor activity and dopamine release in the nucleus accumbens.
    Kosowski AR; Liljequist S
    J Pharmacol Exp Ther; 2004 Nov; 311(2):560-7. PubMed ID: 15256539
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of (-)-6-[2-[4-(3-fluorophenyl)-4-hydroxy-1-piperidinyl]-1-hydroxyethyl]-3,4-dihydro-2(1H)-quinolinone--a potent NR2B-selective N-methyl D-aspartate (NMDA) antagonist for the treatment of pain.
    Kawai M; Ando K; Matsumoto Y; Sakurada I; Hirota M; Nakamura H; Ohta A; Sudo M; Hattori K; Takashima T; Hizue M; Watanabe S; Fujita I; Mizutani M; Kawamura M
    Bioorg Med Chem Lett; 2007 Oct; 17(20):5558-62. PubMed ID: 17766106
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure-affinity relationship studies of non-competitive NMDA receptor antagonists derived from dexoxadrol and etoxadrol.
    Aepkers M; Wünsch B
    Bioorg Med Chem; 2005 Dec; 13(24):6836-49. PubMed ID: 16169732
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The NR2B-selective NMDA receptor antagonist CP-101,606 exacerbates L-DOPA-induced dyskinesia and provides mild potentiation of anti-parkinsonian effects of L-DOPA in the MPTP-lesioned marmoset model of Parkinson's disease.
    Nash JE; Ravenscroft P; McGuire S; Crossman AR; Menniti FS; Brotchie JM
    Exp Neurol; 2004 Aug; 188(2):471-9. PubMed ID: 15246846
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and in vitro opioid receptor functional antagonism of methyl-substituted analogues of (3R)-7-hydroxy-N-[(1S)-1-{[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl}-2-methylpropyl]-1,2,3,4-tetrahydro-3-isoquinolinecarboxamide (JDTic).
    Cueva JP; Cai TB; Mascarella SW; Thomas JB; Navarro HA; Carroll FI
    J Med Chem; 2009 Dec; 52(23):7463-72. PubMed ID: 19954245
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of subunit- and antagonist-specific amino acid residues in the N-Methyl-D-aspartate receptor glutamate-binding pocket.
    Kinarsky L; Feng B; Skifter DA; Morley RM; Sherman S; Jane DE; Monaghan DT
    J Pharmacol Exp Ther; 2005 Jun; 313(3):1066-74. PubMed ID: 15743930
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brain but not spinal NR2B receptor is responsible for the anti-allodynic effect of an NR2B subunit-selective antagonist CP-101,606 in a rat chronic constriction injury model.
    Nakazato E; Kato A; Watanabe S
    Pharmacology; 2005 Jan; 73(1):8-14. PubMed ID: 15452358
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The NMDA receptor NR2B subtype selective antagonist Ro 25-6981 aggravates paroxysmal dyskinesia in the dt(sz) mutant.
    Richter A
    Eur J Pharmacol; 2003 Jan; 458(1-2):107-10. PubMed ID: 12498913
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis, in vitro and in vivo pharmacology of a C-11 labeled analog of CP-101,606, (+/-)threo-1-(4-hydroxyphenyl)-2-[4-hydroxy-4-(p-[11C]methoxyphenyl)piperidino]-1-propanol, as a PET tracer for NR2B subunit-containing NMDA receptors.
    Haradahira T; Maeda J; Okauchi T; Zhang MR; Hojo J; Kida T; Arai T; Yamamoto F; Sasaki S; Maeda M; Suzuki K; Suhara T
    Nucl Med Biol; 2002 Jul; 29(5):517-25. PubMed ID: 12088721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological properties of recombinant human N-methyl-D-aspartate receptors comprising NR1a/NR2A and NR1a/NR2B subunit assemblies expressed in permanently transfected mouse fibroblast cells.
    Priestley T; Laughton P; Myers J; Le Bourdellés B; Kerby J; Whiting PJ
    Mol Pharmacol; 1995 Nov; 48(5):841-8. PubMed ID: 7476914
    [TBL] [Abstract][Full Text] [Related]  

  • 18. State-dependent NMDA receptor antagonism by Ro 8-4304, a novel NR2B selective, non-competitive, voltage-independent antagonist.
    Kew JN; Trube G; Kemp JA
    Br J Pharmacol; 1998 Feb; 123(3):463-72. PubMed ID: 9504387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analogs of 3-hydroxy-1H-1-benzazepine-2,5-dione: structure-activity relationship at N-methyl-D-aspartate receptor glycine sites.
    Guzikowski AP; Cai SX; Espitia SA; Hawkinson JE; Huettner JE; Nogales DF; Tran M; Woodward RM; Weber E; Keana JF
    J Med Chem; 1996 Nov; 39(23):4643-53. PubMed ID: 8917653
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of (3R)-7-hydroxy-N-((1S)-1-[[(3R,4R)-4-(3-hydroxyphenyl)- 3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl)-1,2,3,4-tetrahydro- 3-isoquinolinecarboxamide as a novel potent and selective opioid kappa receptor antagonist.
    Thomas JB; Atkinson RN; Vinson NA; Catanzaro JL; Perretta CL; Fix SE; Mascarella SW; Rothman RB; Xu H; Dersch CM; Cantrell BE; Zimmerman DM; Carroll FI
    J Med Chem; 2003 Jul; 46(14):3127-37. PubMed ID: 12825951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.